Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT): Lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT

Aging Clinical and Experimental Research

Volumn 10, Issue 4, 1998, Pages 316-323

  Bonaccorso, S ^a,b   Lin, A ^a   Song, C ^a,c   Verkerk, R ^d   Kenis, G ^e   Bosmans, E ^e   Scharpe, S ^d   Vandewoude, M ^d   Dossche, A ^d   Maes, M ^a,f  

^a Clinical Research Center for Mental Health of Antwerp   (Belgium)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CARLETON UNIVERSITY   (Canada)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e Eurogenetics   (Belgium)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Cytokines; Dementia; Interleukin 8; Interleukin 6; Tryptophan

Indexed keywords

AMINO ACID; INTERLEUKIN 6; INTERLEUKIN 8; ISOLEUCINE; LEUCINE; PHENYLALANINE; SEROTONIN; TRYPTOPHAN; TYROSINE; VALINE;

ADULT; AGED; AGING; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; IMMUNE SYSTEM; IMMUNOREACTIVITY; MALE; TRYPTOPHAN BRAIN LEVEL; VOLUNTEER;

EID: 13144258727     PISSN: 03949532     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03339794     Document Type: Article

References (63)

1. Carlsson A., Adolfsson R., Aquilonius S.M., Gottfries C.G., Oreland L., Svennerholm L., Winblad B.: Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism. Adv. Biochem. Pharmacol. 23: 295-304, 1980.
2. Bareggi S.R., Franceschi M., Bonini L., Zecca L.. Smime S.: Decreased CSF concentrations of homovanillic acid and aminobutyric acid in Alzheimer's disease. Arch. Neurol. 39: 709-712, 1982.
3. Arai H., Kosaka K., Tizuka R.: Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J. Neurochem. 43: 388-393, 1984.
4. Volicer L., Langlais P.J., Matson W.R., Mark K.A., Gamache P.H.: Serotonergic system in dementia of the Alzheimer type: abnormal forms of 5-hydroxytryptophan and serotonin in cerebrospinal fluid. Arch. Neurol. 42: 1158-1161, 1985.
5. Sparks D.L., Markesbery W.R., Slevin J.T.: Alzheimer's disease: monoamines and spiperone binding reduced in nucleus basalis. Ann. Neurol. 18: 562-565, 1986.
6. Gottfries C.G.: Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia. J. Neural Trans. 30 (Suppl.): 33-43, 1990
7. Tohgi H., Abe T., Takahashi S., Kimura M., Takahashi J., Kikuchi T.: Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neuroscience 141: 9-12, 1992.
8. Mann D.M., Yates P.O.: Serotonin nerve cells in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 46: 96-98, 1983.
9. Yamamoto T., Hirano A.: Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons. Ann Neurol. 17: 573-577, 1985.
10. Bowen D.M., Allen S.J., Benton J.J., Goodhardt M.J., Haan E.A., Palmer A.M., Sims N.R., Smith C.C.T., Spillane J.A., Esiri M.M., Neory D., Snowdon J.J., Wilcock G.K., Davison A.N.: Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J. Neurochem. 41: 266-272, 1983.
11. Perry E.K., Perry R.H., Candy J.M., Fairbairn A.F., Blessed G., Dick D.J., Tomlinson B.E.: Cortical serotonin-2 receptor binding abnormalities in patients with Alzheimer's disease: comparisons with Parkinson's disease. Neurosci. Lett. 51: 353-357, 1984.
12. Reynolds G.P., Arnold L., Rosser M.N., Iversen L.L., Mountjoy C.Q., Roth M.: Reduced binding of H-ketanserin to cortical 5-HT receptors in senile dementia of Alzheimer type. Neurosci. Lett 44: 47-52, 1984.
13. Cassel J.C., Jeltsch H.: Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Neuroscience 69: 1-41, 1995.
14. Blessed G.. Clinical aspects of the senile dementias. In: Roberts P.J. (Ed.), Biochemistry of dementia. Wiley, London, 1980, pp. 1-14.
15. Marielle G., van Luijtelaar P.A., Tonnaer J.A.D.M.. Steinbusch H.W.M.: Aging of the serotonergic system in the rat forebrain: an immunocytochemical and neurochemical study. Neurobiol. Aging 13: 201-215, 1992.
16. Arranz B., Blennow K., Ekman R., Eriksson A , Mansson J.E., Marcusson J.: Brain monoaminergic and neuropeptidergic variations in human aging. J. Neural Transm. 103: 101-115, 1996.
17. Godefroy F., Bassant M.H., Weil-Fugazza J., Lamour Y.: Age-related changes in dopaminergic and serotonergic indices in the rat forebrain. Neurobiol. Aging 10: 187-190, 1990.
18. Timiras P.S., Hudson D.B., Segall P.E.: Lifetime brain serotonin: regional effects of age and precursor availability. Neurobiol. Aging 5: 235-242, 1984.
19. Moretti A., Carfagna N., Trunzo F.: Effect of aging on monoamines and their metabolites in the rat brain. Neurochem. Res. 12: 1035-1039, 1987.
20. Malhado A , Cano J., Santiago M.: The change with age in biogenic amines and their metabolites in the striatum of the rat. Arch. Gerontol. Geriatr. 5: 333-342, 1986.
21. Badawy A.A.B , Morgan C.J., Lovett J.W., Bradley D.M., Thomas R.: Decrease in circulating tryptophan availability to the brain after acute ethanol consumption by normal volunteers- implications for alcohol-induced aggressive behavior and depression. Pharmacopsychiatry 28: 93-97, 1995.
22. Maes M., de Hert M., Claes R., Cosyns P., Suy E.: Serum L-tryptofaan en competitieve aminozuren bij depressieve patienten. Tijdschr. Psychiatrie 31: 267-283, 1989.
23. Curzon G., Sama G.S.: Tryptophan transport to the brain: newer findings and older ones reconsidered. In: Schlossberger H.G., Kochen W., Linzen B., Steinhart H. (Eds.), Progress in Tryptophan and Serotonin Research. Walter De Gruyter, Berlin, 1984, pp. 145-157.
24. Femstrom J.D.: Tryptophan availability and serotonin synthesis in rat brain: effects of experimental diabetes. In: Schlossberger H.G., Kochen W., Linzen B., Steinhart H. (Eds.), Progress in Tryptophan and Serotonin Research. Walter de Gruyter, Berlin, 1984, pp. 161-172.
25. Moir A.T.B., Eccleston D.: The effect of precursor loading in the cerebral metabolism of 5-hydroxyindoles. J. Neurochem. 15: 1093-1108, 1986.
26. Aisen P.S., Davis K.L.: Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am. J. Psychiatry 151: 1105-1113, 1994.
27. McGeer P.L., McGeer E.G.: The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21: 195-218, 1995.
28. McRae A., Dahlstrom A.: Immune responses in brains of Alzheimer's and Parkinson's disease patients: hypothesis and reality. Rev. Neurosci. 3: 79-97, 1992.
29. Hull M., Strauss S., Berger M., Volk B., Bauer J.: The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease. Behav. Brain Res. 78: 37-41, 1996.
30. Fillit H., Ding W., Buee L., Kalman J., Altstiel L., Larlow B., Wolf-Klein G.: Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129: 318-320, 1991.
31. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., Riederer P.: Interleukin-lβ and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett. 202: 17-20, 1995.
32. Sheng J.G., Ito K., Skinner R.D., Mrak R.E., Rovnaghi C.R., van Eldik L J , Griffin WST.: In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheirner pathogenesis. Neurobiol. Aging 17: 761-766, 1996
33. Caruso C., Candore G., Cigna D., di Lorenzo G., Sireci G., Dieli F., Salerno A.: Cytokine production pathway in the elderly, Immunol. Res. 15: 84-90, 1996.
34. Ershler W.B., Sun W.H., Binkley N., Gravenstein S., Volk M.J., Kamoske G., Klopp R.G., Roecker E.B., Daynes R.A., Weindruch R.: Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res. 12: 225-230, 1993.
35. Fagiolo U., Cossarizza A., Scala E., Fanalesbelasio E., Ortolani C., Cozzi E., Monti D., Franceschi C., Paganelli R.: Increased cytokine production in mononuclear cells of healthy elderly people. Eur. J. Immunol 23: 2375-2378, 1993.
36. Mariotti S., Sansoni P., Barbesino G., Caturegli P., Monti D., Cossarizza A., Giacomelli T., Passen G., Fagiolo U., Pinchera A.: Thyroid and other organ-specific autoantibodies in healthy centenarians. Lancet 340: 430, 1992.
37. Sansoni P., Cossarizza A., Brianti V., Fagnoni F., Snelli G., Monti D., Marcato A., Passeri G., Ortolani C., Forti E.: Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 82: 1601-1604, 1993.
38. + cells in human longevity: studies on two healthy centenarians. Eur. J. Immunol. 26: 2030-2034, 1996.
39. Franceschi C., Monti D., Sansoni P., Cossarizza A.: The immunology of exceptional individuals: the lesson of centenarians, Immunol. Today 16: 12-16, 1995.
40. Maes M., Meltzer H.Y., Scharpe S., Bosmans E., Suy E., Minner B., de Meester I., Calabrese J., Vandervorst C., Raus J.. Cosyns P.: Relationships between lower plasma L-tryptophan levels and immune variables in depression. Psychiatry Res. 49: 11-27, 1993.
41. Hu B., Hissong B.D., Carlin J.M.: Interleukin-1 enhances indoleamine 2,3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J. Interferon Cytokine Res 15: 617-624, 1995.
42. Brown R.R., Lee C.M., Kohler P.C., Hank J.A., Storer B.E., Sondel P.M.: Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin-2. Cancer Res. 49: 4941-4944, 1989.
43. Takikawa O., Yoshida R., Yasui H., Hayaishi O.: The. relationship between plasma kynurenine and indoleamine 2,3-dioxygenase activity in the extrahepatic tissues. In: Schlossberger H.G., Kochen W., Linzen B., Steinhart H. (Eds.), Progress in Tryptophan and Serotonin Research. Walter de Gruyter, Berlin, 1984, pp. 517-520.
44. Moroni F., Russi P., Gallo-Mezo M.A., Moneti G., Pellicciari R.: Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine. J. Neurochem. 57: 1630-1635, 1991.
45. Meyer K.C., Arend R.A., Kalayoglu M.V., Rosenthal N.S., Bye G.I., Brown R.R.: Tryptophan metabolism in chronic inflammatory lung disease. J. Lab. Clin. Med. 126: 530-540, 1995.
46. Taylor M.W., Feng G.S.: Relationship between interferongamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5: 2516-2522, 1991.
47. Werner-Felmayer G , Werner E.R., Fuchs D., Hausen A., Reibnegger G., Wachter H.: Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer Res. 50: 2863-2867, 1990.
48. Moldawer L.L., Georgieff M., Lundholm K.: Interleukin-1, tumour necrosis factor-alpha (cachectin) and the pathogenesis of cancer cachexia. Clin. Physiol. 7: 263-274, 1987.
49. Hasselgren P.O., Pedersen P., Sax H.C., Warner B.W., Fischer J.E.: Current concepts of protein turnover and amino acid transport in liver and skeletal muscle during sepsis. Arch. Surg. 123: 992-999, 1988
50. Maes M., Scharpe S., Meltzer H.Y., Okayli G., Bosmans E., D'hondt P., Vanden Bossche B., Cosyns P.: Increased neopterin and Interferon γ secretion and lower availability of L-tryptophan in major depression: further evidence for activation of cell-mediated immunity. Psychiatr. Res. 54: 143-160, 1994.
51. Maes M., Wauters A., Verkerk R., Neels H., Vangastel A., Cosyns P., Scharpe S., Desnyder R.: Lower L-tryptophan availability in depression: a marker of a more generalized disorder in protein metabolism. Neuropsychopharmacol. 15: 243-251, 1996.
52. Maes M., Verkerk R., Vandoolaeghe E., Van Hunsel F., Neels H., Wauters A., Demedts P., Scharpe S.: Serotoninimmune interactions in major depression: lower serum tryptophan as a marker of an immune-inflammatory response. Eur. Arch. Psychiatry Clin. Neurosci. 247: 154-161, 1997.
53. Maes M., Lin A., Bosmans E., Vandoolaeghe E., Bonaccorso S., Kenis G., de Jongh R., Verkerk R., Scharpe S.: Serotoninimmune interactions in detoxified chronic alcoholic patients without apparent liver disease: indicants of immune activation and lower plasma total tryptophan. Psychiatr Res. 78: 151-161, 1998.
54. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, 1987.
55. Turnell D., Cooper J.: Rapid assay for amino acids in serum or urine by precolumn derivatisation and reversed-phase liquid chromatography. Clin. Chem. 28: 527-531, 1982.
56. Maes M., Schotte C., Scharpe S., Martin M., Blockx P.: The effects of glucocorticoids on the availability of L-tryptophan and tyrosine in the plasma of depressed patients. J. Affect. Disord. 18: 121-127, 1990.
57. Yeung J.M., Friedman E.: Effect of aging and diet restriction on monoamines and amino acids in cerebral cortex of Fischer-344 rats. Growth Dev. Aging 55: 275-282, 1991.
58. Bucht G., Adolfsson R., Gottfries C.G., Roos B-E., Winblad B.: Distribution of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in human brain in relation to age, drug influence, agonal status and circadian variation. J. Neural. Transm. 51: 185-203, 1981.
59. Rudman D., Abbasi A.A., Chaudry F., Mattson D.E.. Delayed plasma clearance of phenylalanine and tyrosine in elderly men. J. Am. Geriatr. Soc. 39: 33-38, 1991.
60. Cavaillon J-M.: Les cytokines. Massen, Paris, 1996.
61. Ershler W.B.: Interleukin-6: A cytokine for gerontologists. Geriatr. Biosci. 41: 176-181, 1993 .
62. Jorgenson S., Billc A., Andersen J., Jensen H.V., Olafsson K., Arup P., Moller S.E.: Fluvoxamine treatment of dementia: tryptophan levels. Biol. Psychiatry 34: 587-588, 1993.
63. Vandenabeele P., Fiers W.: Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated "acute phase response" in the brain, Immunol. Today 12: 217-219, 1991.